CA2545054A1 — Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
Assigned to Pharmamar SA · Expires 2005-06-02 · 21y expired
What this patent protects
Methods of treating a human body for cancer are provided. In one aspect, an effective therapeutic amount of paclitaxel is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m2. In a related aspect, an effective therapeutic amount of ET-743 is administere…
USPTO Abstract
Methods of treating a human body for cancer are provided. In one aspect, an effective therapeutic amount of paclitaxel is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m2. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with paclitaxel in a dose range between 80 and 140 mg/m2.
Drugs covered by this patent
- Yondelis (TRABECTEDIN) · Janssen Prods
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.